Investigational drug · Phase 3
QLC5508
Also called: MHB088C
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
9 still active
All registered trials
7
Any phase or sponsor naming "QLC5508"
First trial start
2023
Jun 20, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QLC5508", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced/Metastatic Solid Tumors
- Advanced Malignant Solid Tumor
- Extrapulmonary Neuroendocrine Carcinoma
- Esophageal Squamous Cell Carcinoma (ESCC)
- Advanced Solid Tumor
- Advanced Prostate Cancer
- Extensive-stage Small Cell Lung Cancer
- Prostate Cancer
- Small Cell Lung Cancer Extensive Stage
Approved drugs for the same conditions: Small cell lung cancer · Prostate cancer · Stomach and esophageal cancer · Oncology · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "QLC5508" as an intervention, largest first.
- QLC5508 in Participants With Metastatic Prostate CancerPivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07632690 · 700 participants (planned) · Start Jun 20, 2026 · Primary completion Jun 20, 2028
Drug: QLC5508; Docetaxel · For: Prostate Cancer
- A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung CancerPivotal-lookingRecruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07802821 · 556 participants (planned) · Start Oct 27, 2026 · Primary completion Mar 15, 2029
Drug: QLC5508; QL2107 and 4 more · For: Extensive-stage Small Cell Lung Cancer
Sites: Shanghai, China
- QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell CarcinomaPivotal-lookingRecruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07463573 · 466 participants (planned) · Start Apr 20, 2026 · Primary completion Jun 5, 2028
Drug: QLC5508; Investigator's Choice of Chemotherapy (docetaxel, paclitaxel, or Irinotecan Hydrochloride) · For: Esophageal Squamous Cell Carcinoma (ESCC)
Sites: Beijing, China
Qilu Pharmaceutical Co., Ltd.Industry
NCT07256782 · 444 participants (planned) · Start Oct 24, 2025 · Primary completion Oct 2026
Drug: QLC5508; QL1706 and 5 more · For: Advanced Solid Tumor
Sites: Shanghai, China
- QLC5508 vs. Investigator's Choice Chemotherapy in Advanced Extrapulmonary Neuroendocrine CarcinomaPivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07894211 · 270 participants (planned) · Start Oct 26, 2026 · Primary completion Mar 26, 2029
Drug: Investigator's Choice Chemotherapy (FOLFIRI or FOLFOX regimen); QLC5508 · For: Extrapulmonary Neuroendocrine Carcinoma
Qilu Pharmaceutical Co., Ltd.Industry
NCT07198633 · 212 participants (planned) · Start Nov 5, 2025 · Primary completion Dec 2026
Drug: QLC5508; abiraterone acetate and 2 more · For: Advanced Prostate Cancer
Sites: Tianjin, China
Qilu Pharmaceutical Co., Ltd.Industry
NCT07620041 · 48 participants (planned) · Start Jun 9, 2026 · Primary completion Dec 5, 2026
Drug: QLC5508 (Investigational Product / Formulation T); QLC5508 (Reference Product / Formulation R) and 3 more · For: Refractory or Relapsed Solid Tumors
Sites: Changchun, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced/Metastatic Solid Tumors
- PetosemtamabMCLA-158, GEN1158Phase 35 trials
Genmab · Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Advanced/Metastatic Solid Tumors
- SYS6043Phase 35 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Advanced Solid Tumors, Advanced/Metastatic Solid Tumors, HCC - Hepatocellular Carcinoma
- ADG126Phase 23 trials
Adagene Inc · Advanced/Metastatic Solid Tumors, Solid Tumor, Advanced Liver Cancers
- HRS-6719Phase 21 trial
Shandong Suncadia Medicine Co., Ltd. · Advanced/Metastatic Solid Tumors
- SYS6088Phase 21 trial
CSPC Megalith Biopharmaceutical Co.,Ltd. · Advanced/Metastatic Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.